«Previous Article|Table of Contents|Next Article»

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:

2024 18

Page:

3506-3512

Research Field:

Publishing date:

Info

Title:

The clinical value of miR-330 combined with MORC2 detection in prognostic evaluation of cervical cancer

Author(s):

ZHAO Danling¹; SHI Xiaoyuan²; DONG Yan¹; BAO Mingzhu¹; JI Yinhua¹

1.Department of Gynaecology,Shuyang Hospital Affiliated to Xuzhou Medical University,Jiangsu Suqian 223800,China;2.Department of Gynaecology,Suqian First People's Hospital,Jiangsu Suqian 223800,China.

Keywords:

cervical cancer; miR-330; MORC2; clinical value

PACS:

R737.33

DOI:

10.3969/j.issn.1672-4992.2024.18.017

Abstract:

Objective:To study the clinical value of miR-330 combined with MORC2 detection in the assessment of cervical cancer status and prognosis.Methods:81 patients with cervical cancer (CVC group) and patients with benign cervical diseases (control group) diagnosed and treated from January 2018 to January 2022 were selected as the research subjects.Real-time fluorescence quantitative PCR was used to detect the expression of miR-330 and MORC2 and analyze the relationship with clinical pathological factors.The ROC curve was used to analyze the sensitivity and specificity of miR-330 combined with MORC2 in predicting poor 2-year prognosis of cervical cancer.The risk factors for cervical cancer death were analyzed with multivariate Logistic regression.Kaplan-Meier method was used to analyze the relationship between the expression of miR-330 and MORC2 and survival time.Results:The expression of miR-330 and MORC2 in the tumor tissue of cervical cancer patients in the CVC group was significantly higher than that in the adjacent tissue and the control group (P£¼0.05).The expression of miR-330 and MORC2 in patients with poorly differentiated,malignant ascites,myometrial invasion depth ¡Ý1/2,lymph node metastasis,distant metastasis,and stage III-IV cervical cancer were significantly higher than that in patients with moderate-to-well differentiation and no malignant ascites,myometrial invasion depth <1/2,no lymph node metastasis,no distant metastasis and stage I-II patients.The sensitivity,specificity and AUC of MORC2 combined with miR-330 in predicting poor 2-year prognosis of cervical cancer were higher than those of miR-330,MORC2,tumor differentiation,malignant ascites,myometrial invasion depth,lymph node metastasis,distant metastasis and FIGO staging (P£¼0.05).miR-330¡Ý0.89,MORC2¡Ý0.72,poorly differentiated,malignant ascites,myometrial invasion depth ¡Ý1/2,lymph node metastasis,distant metastasis,and FIGO stage III-IV were independent risk factors for death from cervical cancer (P£¼0.05).In the CVC group,the median survival time of cervical cancer patients with miR-330¡Ý0.89 and MORC2¡Ý0.72 was significantly lower than that of other patients (miR-330<0.89 or MORC2<0.72) £Ûmedian survival time (24.1¡À4.5)months vs (38.7¡À6.2)months,Log Rank=21.462,P£¼0.05£Ý.Conclusion:The expression of miR-330 and MORC2 is significantly increased in patients with cervical cancer,which has important clinical value in the assessment of the condition and prognosis of cervical cancer.The detection of both can significantly improve the sensitivity and specificity in predicting poor prognosis of cervical cancer.

References:

£Û1£Ý DOGHISH AS,ALI MA,ELYAN SS,et al.miRNAs role in cervical cancer pathogenesis and targeted therapy:Signaling pathways interplay£ÛJ£Ý.Pathol Res Pract,2023,244(4):154386.
£Û2£Ý SWANSON AA,PANTANOWITZ L.The evolution of cervical cancer screening£ÛJ£Ý.J Am Soc Cytopathol,2024,13(1):10-15.
£Û3£Ý RUNGKAMOLTIP P,TEMISAK S,PIBOONPRAI K,et al.Rapid and ultrasensitive detection of circulating human papillomavirus E7 cell-free DNA as a cervical cancer biomarker£ÛJ£Ý.Exp Biol Med (Maywood),2021,246(6):654-666.
£Û4£Ý BARHOUM A,J FORSTER R.Label-free electrochemical immunosensor for picomolar detection of the cervical cancer biomarker MCM5£ÛJ£Ý.Anal Chim Acta,2022,1225(2):340226.
£Û5£Ý ¼¾Ó¡»ª,ÕÅÝí.miRNA-330ÔÚ¹¬¾±°©×éÖ¯Öеıí´ï¼°¶Ô°©Ï¸°û»îÐÔµÄÓ°Ïì£ÛJ£Ý.±±»ª´óѧѧ±¨(×ÔÈ»¿Æѧ°æ),2022,23(05):591-595. JI YH,ZHANG B.Expression of miRNA-330 in cervical cancer tissue and its effect on cancer cell activity£ÛJ£Ý.Journal of Beihua University(Natural Science),2022,23(05):591-595.
£Û6£Ý ZHOU Q,XIE Y,WANG L,et al.LncRNA EWSAT1 upregulates CPEB4 via miR-330-5p to promote cervical cancer development£ÛJ£Ý.Mol Cell Biochem,2020,471(1-2):177-188.
£Û7£Ý TAN Y,ZHENG T,SU Z,et al.Alternative polyadenylation reprogramming of MORC2 induced by NUDT21 loss promotes KIRC carcinogenesis£ÛJ£Ý.JCI Insight,2023,8(18):e162893.
£Û8£Ý LIU HY,LIU YY,YANG F,et al.Acetylation of MORC2 by NAT10 regulates cell-cycle checkpoint control and resistance to DNA-damaging chemotherapy and radiotherapy in breast cancer£ÛJ£Ý.Nucleic Acids Res,2020,48(7):3638-3656.
£Û9£Ý GAVINSKI K,DINARDO D.Cervical cancer screening£ÛJ£Ý.Med Clin North Am,2023,107(2):259-269.
£Û10£Ý MART¦PNEZ-RODR¦PGUEZ F,LIMONES-GONZ¦BLEZ JE,MENDOZA-ALMANZA B,et al.Understanding cervical cancer through proteomics£ÛJ£Ý.Cells,2021,10(8):1854.
£Û11£Ý ÅáÏò´º,ÍõÖ¾Á«.MicroRNAµ÷¿ØÉÏƤ¼äÖÊת»¯¶Ô¹¬¾±°©ÇÖϮתÒÆÐÔÓ°ÏìµÄÑо¿½øÕ¹£ÛJ£Ý.ÏÖ´úÖ×Áöҽѧ£¬2021,29(02):341-345. PEI XC,WANG ZL.Research progress of effect of microRNA regulation of EMT on invasion and metastasis of cervical cancer£ÛJ£Ý.Modern Oncology,2021,29(02):341-345.
£Û12£Ý ÖÜÑ©£¬ÏÄÀö÷.΢СRNAÔÚ¹¬¾±°©ÖÐ×÷ÓõÄÑо¿½øÕ¹£ÛJ£Ý.ÏÖ´úÖ×Áöҽѧ£¬2019,27(17):3164-3166. ZHOU X,XIA LM.Research on the role of microRNAs in cervical cancer£ÛJ£Ý.Modern Oncology,2019,27(17):3164-3166.
£Û13£Ý TABRIZI-NEZHADI P,MOTIEGHADER H,MALEKI M,et al.Application of protein-protein interaction network analysis in order to identify cervical cancer miRNA and mRNA biomarkers£ÛJ£Ý.Scientific World Journal,2023,2023(7):6626279.
£Û14£Ý WANG W,LIU L,TIAN Y.miR-19-3p targets PTEN to regulate cervical cancer cell proliferation,invasion,and autophagy£ÛJ£Ý.Genet Res (Camb),2023,2023(5):4784500.
£Û15£Ý ÅÓȻȻ£¬ÀîÑº«ÀöƼ.ѪÇåmiR-367¡¢miR-383±í´ïˮƽÓ빬¾±°©¸ùÖÎÊõºó¸´·¢¼°Ô¤ºóµÄÏà¹ØÐÔ£ÛJ£Ý.ÏÖ´úÖ×Áöҽѧ£¬2021,29(7):1196-1200. PANG RR,LI Y,HAN LP.The correlation between the expressions of miR-367,miR-383 in serum and the recurrence,prognosis of cervical cancer after radical operation£ÛJ£Ý.Modern Oncology,2021,29(7):1196-1200.
£Û16£Ý HUANG Y,SUN H,MA X,et al.HLA-F-AS1/miR-330-3p/PFN1 axis promotes colorectal cancer progression£ÛJ£Ý.Life Sci,2020,254(9):117180.
£Û17£Ý SHIRJANG S,MANSOORI B,MOHAMMADI A,et al.miR-330 regulates colorectal cancer oncogenesis by targeting BACH1£ÛJ£Ý.Adv Pharm Bull,2020,10(3):444-451.
£Û18£Ý WANG Y,LIU Z,REN X,et al.Hsa-miR-330-5p aggravates thyroid carcinoma via targeting FOXE1£ÛJ£Ý.J Oncol,2021,2021(4):1070365.
£Û19£Ý RAHMATI Y,ALIVAND M,MOLLANOORI H.MiR-330-3p and miR-485-5p as biomarkers for glioblastoma:An integrated bioinformatics and experimental study£ÛJ£Ý.Comput Biol Chem,2021,92(8):107458.
£Û20£Ý CHU S,LI Y,WU B,et al.METTL3 promotes the growth and invasion of melanoma cells by regulating the lncRNA SNHG3/miR-330-5p axis£ÛJ£Ý.Cell Transplant,2023,32(10):9636897231188300.
£Û21£Ý HOU S,ZHANG X,YANG J.Long non-coding RNA ABHD11-AS1 facilitates the progression of cervical cancer by competitively binding to miR-330-5p and upregulating MARK2£ÛJ£Ý.Exp Cell Res,2022,410(1):112929.
£Û22£Ý LIU YY,LIU HY,YU TJ,et al.O-GlcNAcylation of MORC2 at threonine 556 by OGT couples TGF-¦Â signaling to breast cancer progression£ÛJ£Ý.Cell Death Differ,2022,29(4):861-873.
£Û23£Ý ZHANG FL,YANG SY,LIAO L,et al.Dynamic SUMOylation of MORC2 orchestrates chromatin remodelling and DNA repair in response to DNA damage and drives chemoresistance in breast cancer£ÛJ£Ý.Theranostics,2023,13(3):973-990.
£Û24£Ý SAROHA HS,KUMAR GUDDETI R,JACOB JP,et al.MORC2/¦Â-catenin signaling axis promotes proliferation and migration of breast cancer cells£ÛJ£Ý.Med Oncol,2022,39(9):135.
£Û25£Ý GUDDETI RK,PACHARLA H,YELLAPU NK,et al.MORC2 and MAX contributes to the expression of glycolytic enzymes,breast cancer cell proliferation and migration£ÛJ£Ý.Med Oncol,2023,40(3):102.
£Û26£Ý XIAOHONG L,CHAO L,ZHENLUO D,et al.High expression of MORC2 predicts worse neoadjuvant chemotherapy efficacy in triple negative breast cancer£ÛJ£Ý.Medicine,2023,102(25):21-34.
£Û27£Ý YANG F,XIE HY,YANG LF,et al.Stabilization of MORC2 by estrogen and antiestrogens through GPER1-PRKACA-CMA pathway contributes to estrogen-induced proliferation and endocrine resistance of breast cancer cells£ÛJ£Ý.Autophagy,2020,16(6):1061-1076.
£Û28£Ý DING S,HUANG X,ZHU J,et al.ADH7,miR-3065 and LINC01133 are associated with cervical cancer progression in different age groups£ÛJ£Ý.Oncol Lett,2020,19(3):2326-2338.
£Û29£Ý ZHAO H,HU GM,WANG WL,et al.LncRNA TDRG1 functions as an oncogene in cervical cancer through sponging miR-330-5p to modulate ELK1 expression£ÛJ£Ý.Eur Rev Med Pharmacol Sci,2019,23(17):7295-7306.
£Û30£Ý CUI L,NAI M,ZHANG K,et al.lncRNA WT1-AS inhibits the aggressiveness of cervical cancer cell via regulating p53 expression via sponging miR-330-5p£ÛJ£Ý.Cancer Manag Res,2019,11(7):651-667.
£Û31£Ý SUN D,CAO R,HAN L,et al.Long noncoding RNA brain cytoplasmic RNA 1 induces cisplatin-resistance of cervical cancer cells by sponging microRNA-330-5p and upregulating high-mobility group box 3£ÛJ£Ý.Gynecol Obstet Invest,2022,87(3-4):200-210.
£Û32£Ý JAFARZADEH A,PAKNAHAD MH,NEMATI M,et al.Dysregulated expression and functions of microRNA-330 in cancers:A potential therapeutic target£ÛJ£Ý.Biomed Pharmacother,2022,146(8):112600.

Memo

Memo:

½­ËÕÊ¡ËÞǨÊпÆѧ¼¼Êõ¾ÖÏîÄ¿£¨±àºÅ£ºZ202313)

Common functions

Last Update: 1900-01-01